Subscribe to Rupya
|
Cadila Healthcare Ltd (CHL) has informed the market that the company has come out with a decision on the meeting that was held on on Feb 25th hat they will allocate 1 (One) Equity Share of Rs. 5/- each fully paid-up for every 2 (Two) Equity Shares of Rs. 5/- each based on the record date that will eb announced later.
Strides Arcolab Ltd has informed the market that they have launched on Retail basis of Starflu (Oseltamivir) for the treatment of ‘Influenza – A (H1N1).This will be now available in all registered pharma shops.This has given some hike in stock prize , this is second company to come out with retail launch of swine flu cure.
Natco Pharma launches Swine Flu medicine its medicine and not a Vaccine , Its called NatFlu which is generic version of TamiFlu – Oseltamivir whioch is considered as a cure for Swine Flu .They are costing 480 rs per Bottle which has 10 capsules and they said its available in all licensed Pharmacies.
>Natco Pharma rose after the US drug regulator accepted new drug application from its partner Mylan Inc for a generic version of Teva Pharmaceutical’ blockbuster Copaxone
>Anuh Pharma rose after the company said its manufacturing facility will receive European Good Manufacturing Practices certificate.
>Orchid Chemicals & Pharmaceuticals rose after the company got US drug regulators’ nod for piperacillin-tazobactam antibiotic in injection forms with a 180-day marketing exclusivity.
Panacea Biotec Ltd has informed the market that the Company has received a largest order from UNICEF for 3 years starting from 2010 for supply of its EasyFive (pentavalent vaccine),the orderis valued around USD 222.37 million (over Rs 1,067 Crores).
What is EasyFive Vaccine from Panacea
EasyFive is world’s first fully liquid pentavalent vaccine introduced in India by Panacea Biotec in January 2005, which immunizes children against five dreadful diseases (Diptheria, Tetanus, wholecellPertussis, Hepatitis B and Hemophilus Influenza Type b) of early childhood.
Divis lab which was battered almost for 2 days because of poor qtr performance had also other bad news that was spread by mails and messages circulating regarding an alleged pledging of promoter’s shareholding in the Company with India Bulls or some institution, After this Divi’s clarified it to the stock exchange that there is no pledge, whatsoever, of any shares held by the promoter in Divi’s Laboratories Ltd. Infact, the promoter does not have any loans from any bank or institution.Not sure if they are followign this has standard now to batter the stock and then get it at higher price.
Dabur India informed the market that they had bought 72.15% stake in Fem Care Pharma for Rs 203.7 crore ,which will be paid in full cash , They want to use this as the platform to enter into skin care market.They still have to buy an addtional 20 percent stake in Fem care which is required by takeover regulations act of india.Fem care Pharma closed the market yesterday at 656 or so up by 13 rs.
Panacea Biotec informed the market that it has received order worth 35 million US dollars from UNICEF to supply pentavalent vaccines, the order is almost worth 140 crore rs in indian money, This is forst time i have seen a unicef order coming to a indian medical company .On the financial side The company’s net profit fell 27.9% to Rs 34.05 crore on 3.8% decline in sales to Rs 224.48 crore in Q1 June 2008 over Q1 June 2007.
Biocon net profit declines 33.10% to Rs 30.01 crore in the first Qtr for june ending 2008-2009 compared to Rs 44.86 crore in same QOQ Previous year 2007. Sales declined 2.74% to Rs 221.18 crore in the first Qtr for june ending 2008-2009 compared to Rs 227.40 crore in same QOQ Previous year 2007.
Jubilant Organosys announces its first QTR Results for 2008-2009.Net profit was at Rs 12.76 crore versus Rs 142.9 crore when compared to the same QTR for previous year , ok i understand is the figure wrong or something no it is right they had a huge forex loss of 107.6 crore this qtr but the same was like 82 crore gain previous year same qtr. Q1 net sales is at Rs 826.6 crore versus Rs 540 crore on YoY basis.
So on thursday ranbaxy was down like to 216 rs because ranbaxy told the market that they are not interested in hostile takeover , may be thats the strategy they say it and get orchid chemical price down and had Solrex acquire 3.32% stake in Orchid Chemicals on Friday, reports CNBC-TV18. The company shareholding in the Indian Pharmaceuticals major has reached 14.72%, which is close to 15% open offer trigger. Sources said other Ranbaxy promoter group companies might have also garnered shares in Orchid.
Orchid Chemicals & Pharmaceuticals Ltd has informed the market that the Company is announcing, on April 10, 2008 the formation of its wholly owned subsidiary in Japan called Orchid Pharma Japan K K (Orchid Japan). Orchid Japan, is headquartered in Tokyo, will drive Orchid’s foray into the high potential and growing Japanese generics market.
Ranbaxy commented that they don’t believe in hostile takeover , this statement was enough to sell orchid chemicals which rose from prev week of 140 rs or so to this weeks 240 rs .There was speculation that Solrex Pharmaceuticals, which recently increased its holding in Orchid to 11.4% is controlled by Ranbaxy. Orchid stock had spurted in the last two days on such buzz.The acquisition of Orchid shares by Solrex Pharmaceuticals through open market purchases raised expectations that Ranbaxy plans a hostile takeover of Orchid Chemicals
Orchid Chemicals was hammered today by 40 percent or so and its trading at 128 and it closed the market on friday at 208.60 , infact hindu has reconmmended a Buy on this stock on saturday .The traded quantity in the stock is unusally high.
Hindu Recommends a Buy for Orchid Chemicals on saturday
Update: Reason for the sell off
The Orchid management told CNBC-TV18 that they have sold 7% of their stake due to margin calls.After Bear Stearns transferred over 10 lakh Orchid shares, the stock price was under considerable pressure. As the margin calls positions are being cleared, they have no further plans to sell more shares, the management said.
Nicholos piramal which changed its name to Piramal Healthcare like previous week or so now has a new identity or logo , They call the identity as a Gyan Mudra .The stock price of Nicholos piramal went up by 16.50 rs or 6 percent in BSE today.You can see the new Gyan Mudra identity of Piramal Healthcare in the picture below.
About Aurobindo Pharma
| One of the largest API manufacturers in Asia, Aurobindo Pharma has commercialised over hundred APIs. Aurobindo’s products are spread over six major areas encompassing Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. |  |
Aurobindo’s R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo develops new drug delivery systems, dosage formulations and applies new technology for better processes.
Sector :Pharmaceuticals – Bulk Drugs
Stock Price
Aurobindo Pharma is trading at 304 rs or so which was on march 7th 2008 and its just 7 times the EPs of 43 or so , while considering other phrama company at this price its considered a good buy.
Track Aurobindo Stock Price here.
Budget Benefits
•Reduction of excise duty from 16% to 8% is a positive for all pharma companies .
•Emphasis on allocating funds for the eradication of HIV/AIDS and polio .
Read the rest of this entry »
Nicholas Piramal India Ltd informed the market that at its meeting held on March 03, 2008, has approved the proposal for change of name of the Company from “Nicholas Piramal India Ltd” to “Piramal Healthcare Ltd”.The Health Sector dint see much red sides today and this scrip also dint go much down today.
Shasun Chemicals & Drugs Ltd saw some movement in the price today after it informed the market that they have entered into a non-exclusive licensing agreement with Merck & Co., Inc.This will bring more business from Merck.
Jubilant Organosys Ltd informed the market that it has bagegd new contracts worth US $ 92 million for its Proprietary Products and Exclusive Synthesis segment under CRAMS business for the present calendar year (CY 2008).
Bliss GVS Pharma rose 5433.33% to Rs 8.30 crore in Qtr Dec 2007 compared to Rs 0.15 crore QOQ in Dec 2006. Sales rose 2084.31% to Rs 22.28 crore in Qtr Dec 2007 compared to Rs 1.02 crore QOQ in Dec 2006.
Orchid Chemicals & Pharmaceuticals rose 91.07% to Rs 54.11 crore in qtr Dec 2007 as against Rs 28.32 crore in qtr Dec 2006. Sales rose 39.36% to Rs 332.69 crore in qtr Dec 2007 as against Rs 238.73 crore in qtr Dec 2006.
Sanjivani Paranteral Ltd has announced the market that it has entered into supply contract for a period of two years with Government of Maharashtra by DMER for the supply of its 9 products to more than 100 Civil Hospitals & Medical Collages in entire Maharashtra State Government’s .
Bliss GVS Pharma Ltd has informed BSE that the Company has received an order of Rs 25.00 crores for supply of Anti malarial Drugs for African Countries.
Aurobindo Pharma Ltd has posted a net profit of Rs 1009.20 million for the quarter ended September 30, 2007 as compared to Rs 546.40 million for the quarter ended September 30, 2006. Total Income has increased from Rs 4673.00 million for the quarter ended September 30, 2006 to Rs 6492.00 million for the quarter ended September 30, 2007.the result is really good one can pick aurobindo pharma on dips.
Torrent Pharmaceuticals has posted a net profit after tax of Rs 373.10 million for
the quarter ended September 30, 2007 as compared to Rs 256.40 million
for the quarter ended September 30, 2006. Total Income has increased
from Rs 2301.60 million for the quarter ended September 30, 2006 to Rs
2595.50 million for the quarter ended September 30, 2007.
Cadila Healthcare has posted a net profit of Rs 713 million for the quarter ended September 30, 2007 as compared to Rs 655 million for the quarter ended September 30, 2006. Total Income has increased from Rs 4014 million for the quarter ended September 30, 2006 to Rs 4535 million for the quarter ended September 30, 2007.
Dr Reddy has posted a net profit of Rs 1250.00 million for the quarter ended
September 30, 2007 as compared to Rs 2726.60 million for the quarter ended
September 30, 2006. Total Income has decreased from Rs 9489.60 million for
the quarter ended September 30, 2006 to Rs 9240.40 million for the quarter
ended September 30, 2007.
Biocon has announced its second quarter results. The company’s Q2 net profit up at Rs 54 crore (Rs 540 million) versus Rs 45 crore (Rs 450 million).They are betting high on enzymes and the enxt quarter will see a good sales on it , so we can buy biocon on dips , i say to buy on dips is i dont see much of a increase ion sales or profit compares to prev qtr .
Lupin 1st quarter 2007 results gives good dosage to shareholders
NetProfit
Lupin has posted a net profit of Rs 783.80 million for the quarter ended June 30, 2007 as compared to Rs 506.50 million for the quarter ended June 30, 2006.
Income
Total Income (net of excise) has increased from Rs 4951.60 million for the quarter ended June 30, 2006 to Rs 6168.90 million for the quarter ended June 30, 2007.
Ranbaxy gives better than expected results for the second Quarter of 2007
NetProfit
Net profit after tax of Rs 2911.50 million for the quarter ended June 30, 2007 as compared to Rs 998.30 million for the quarter ended June 30, 2006.
Total Income
Total Income (net of excise) has increased from Rs 10837.80 million for the quarter ended June 30, 2006 to Rs 10880.00 million for the quarter ended June 30, 2007.
Jubilant Organosys has announced its first quarter results.
Net Profit
Net profit of Rs 142.9 crore versus Rs 46.1 crore in corresponding quarter of previous year.
Net sales
Net sales stood at Rs 540 crore as against Rs 412.4 crore .
After going through teh results page i found out other income was lot during this quarter which has hekped in spurting the Profit .
Fortis Heathcare clarifies on news that started appearing in almost every daily about
the 6200 crore join venture project between DLF and Fortis , they sais there is no suich deal that has newly developed and also further clarified
that the join venture wa their with DLF even before the IPO and the Prospectus of the Company dated April 25, 2007 had mentioned the same. Further,
they told that the MOU has not come out into any defenetive arrangement or anything .
| Result (Rs cr) | Mar-07 | Dec-06 | Sep-06 | Jun-06 | Mar-06 |
| Net Sales | 252.59 | 149.62 | 161.37 | 160.84 | 127.09 |
| Other Income | 3.40 | 2.45 | 3.41 | 4.36 | 2.58 |
| Total Income | 255.99 | 152.07 | 164.77 | 165.20 | 129.68 |
| Expenditure | -138.70 | -107.08 | -117.88 | -114.77 | -88.30 |
| Operating Profit | 117.29 | 44.99 | 46.89 | 50.43 | 41.38 |
| Interest | -4.06 | -3.81 | -0.65 | -2.06 | -2.14 |
| Gross Profit | 113.23 | 41.18 | 46.24 | 48.37 | 39.24 |
| Depreciation | -8.04 | -5.87 | -4.15 | -4.26 | -3.86 |
| Profit before Tax | 105.19 | 35.31 | 42.09 | 44.11 | 35.38 |
| Tax | -4.21 | -2.58 | -10.81 | -17.36 | -12.48 |
| Profit after Tax | 100.98 | 32.73 | 31.28 | 26.75 | 22.89 |
| Net Profit | 100.98 | 32.73 | 31.28 | 26.75 | 22.89 |
| Equity Capital | 12.91 | 12.82 | 12.82 | 12.82 | 12.82 |
Dr Reddy’s has declared its fourth quarter and FY07 results. The company’s FY07 net profit was at USD 215 million and revenue of USD 1.5 billion (US GAAP).
Sun Pharma has declared its fourth quarter and FY07 results. The company’s FY07 net profit was at Rs 629 crore versus Rs 461.3 crore on standalone basis.
Polar Pharma and CUPID gets two seperate order each for supply of 85 million pieces (mpc.) of Male Condoms amounting to Rs 1067.94 lacs for one order from Ministry of Health & Family Welfare, Government of India.This is what they say raining condoms.:)
Jubilant Organosys has announced its Q4FY07 results. The company has reported net profit of Rs 63.8 crore in fourth quarter.
GlaxoSmithKline Pharmaceuticals has come out with Q1CY07 results. The company’s net profit has increased to Rs 111 crore from Rs 101 crore.
Nagarjuna Fertilisers has announced its FY07 results. The company has posted net profit of Rs 31.71 crore versus Rs 66.9 crore in corresponding quarter of previous year.
The company has posted net profit of Rs 14.95 crore in fourth quarter versus Rs 12.7 crore in corresponding quarter of previous year.
Biocon Ltd has announced the launch of its new Nephrology Division and a comprehensive portfolio of renal therapy products on March 08, 2007. The products were launched by Smt. Sudha Murthy at a press conference. The Company’s Nephrotogy division is committed to finding solutions to kidney disorders using the highest standards of biotherapeutics and will simultaneously strive towards reducing the risks of the disease in the future, through progressive research and innovative therapies
With reference to the earlier announcement dated October 12, 2006 regarding “Granules India Signs MoU with Biocause of China”, Granules India Ltd has informed BSE that the Agreement entered between the Company and Hubei Biocause Heilen Pharmaceutical Company Ltd, China for setting up of a Joint Venture Company in China has been approved by the Government of China.
Dr Lal Path Labs Private Limited (LPL) was established in 1949 by the late Dr (Major) S K Lal, a pioneer in the field of pathology who had been trained in the Army and later at the Cook County Hospital, Chicago, USA . He used his expertise and knowledge to establish an organisation that was destined to become the first Pathology Laboratory of repute in Delhi and Northern India.
The company is also on the look out for acquiring suitable pathology labs in the country. Plans are to achieve a turnover target of Rs 200 crore in three years from the current Rs 75 crore, O P Manchanda, chief operating officer, said.
“We are looking at the option of IPO route to fund our expansion plans for the future, as venture capitalists exit over a period of time. The timing of the IPO will be decided considering the projects and growth targets
The Company is contemplating to acquire about 50 acres of land in Jawaharlal Nehru Pharma City in Vishakapatna for its future manufacturing expansion needs. The proposed investment is in the order of Rs 500 crores over five years.
